YARW (Yarrow Bioscience) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
8 GF Score
Price $35.07
View Full Analysis

What is Yarrow Bioscience ROCE %?

Yarrow Bioscience YARW +6.15% 8 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates YARW with a GF Score™ of 8/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Yarrow Bioscience's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Yarrow Bioscience  (NAS:YARW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Yarrow Bioscience ROCE % Related Terms

Yarrow Bioscience ROCE % Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience ROCE % Chart

Yarrow Bioscience Annual Data
Trend Dec25
ROCE %
0.00

Yarrow Bioscience Semi-Annual Data
Dec25
ROCE % 0.00
YARW
8GF Score
Yarrow Bioscience Inc YARW
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience ROCE % Calculation

Yarrow Bioscience's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: . 20 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: . 20 )(A: Dec. 2025 )
=/( ( ( - ) + ( - ) )/ )
=/( (+)/ )
=/
= %

Yarrow Bioscience's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: . 20 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: . 20 )(Q: Dec. 2025 )
=/( ( ( - ) + ( - ) )/ )
=/( ( + )/ )
=/
= %

(1) Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Yarrow Bioscience (YARW) has a ROCE % of 0.00% as of Dec. 2025.
Is Yarrow Bioscience's ROCE % too high?
Yarrow Bioscience's current ROCE % is 0.00%. Overall, Yarrow Bioscience has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's ROCE % compare to ?
Yarrow Bioscience's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Yarrow Bioscience's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Yarrow Bioscience's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yarrow Bioscience Business Description

Comparable Companies
Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
8GF Score

Get the complete analysis for YARW

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.07
Price